Board of Directors
William R. Ringo has served as Chairman of our Board of Directors since April 16, 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was the Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizer's overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the Board of Directors after serving as interim Chief Executive Officer from June to September 2003. Since February 2011, Mr. Ringo has served on the borad of directors of Onyx Pharmaceuticals, Inc. He also serves on the board of directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region. Mr. Ringo is a senior advisor toe Barclays Healthcare Group and a strategic advisor to Sofinnova Ventures. He received a B.S. in Business Administration and an M.B.A. from the University of Dayton.
Paul B. Cleveland has served as a member of our Board of Directors since November 2008. From June 2014 he has served as President and CFO of Celladon Corporation. From February to August 2013, when the company was acquired by Johnson & Johnson, he served as Executive Vice President of Strategy and Chief Financial Officer at Aragon Pharmaceuticals, a privately held, small-molecule drug discovery company. Before joining Aragon, Mr. Cleveland served as General Partner and Chief Operating Officer at Mohr Davidow Ventures from April 2011 to January 2013 and prior to that from January 2006 until March 2011, he was Executive Vice President, Corporate Development and Chief Financial Officer for Affymax. Earlier in his career he was an investment banker at J.P. Morgan Chase and Co. and a predecessor firm, Hambrecht & Quist, and a corporate lawyer at Cooley Godward LLP, Sidley Austin LLP, and Davis Polk & Wardwell. Mr. Cleveland holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.
Stephen G. Dilly, M.B.B.S., Ph.D., has served as a member of our Board of Directors since March 2010. From May 2014 he has served as CEO of Allergen Research Corporation. Prior to that, from December 2011 to December 2012 Dr. Dilly was CEO of PhotoThera, Inc., a medical device company with a product in Phase III clinical trials for the treatment of ischemic stroke. From 2006 to 2011, Dr. Dilly served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.
Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has over thirty years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986, Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute, the board of directors and as a member of the Executive Committee of the Alliance for Regenerative Medicine, the board of trustees for The Buck Institute for Research on Aging, and the Dean's Advisory Board for the University of Michigan School of Public Health.. Mr. Lanphier holds a B.A. in biochemistry from Knox College.
|Holdings: 1,751,054 shares View Transactions|
|Date||Type||Shares Traded||Price Range|
|Feb 17, 2015||Automatic Sell||25,000||15.69|
|Feb 17, 2015||Option Execute||25,000||6.82|
|Jan 16, 2015||Automatic Sell||10,000||14.29|
|Jan 16, 2015||Option Execute||10,000||6.82|
|Jan 15, 2015||Automatic Sell||15,000||14.09 - 14.97|
|Jan 15, 2015||Option Execute||15,000||6.82|
|Dec 15, 2014||Disposition (Non Open Market)||96,533||14.74|
|Dec 15, 2014||Automatic Sell||25,000||14.79 - 16.47|
|Dec 15, 2014||Option Execute||25,000||4.11|
|Dec 11, 2014||Acquisition (Non Open Market)||125,000||n/a|
|Nov 17, 2014||Automatic Sell||25,000||11.23|
|Nov 17, 2014||Option Execute||25,000||4.11|
|Oct 15, 2014||Automatic Sell||25,000||10.49|
|Oct 15, 2014||Option Execute||25,000||4.11|
|Sep 15, 2014||Automatic Sell||25,000||12.14|
|Sep 15, 2014||Option Execute||25,000||4.11|
|Aug 15, 2014||Automatic Sell||25,000||13.95|
|Aug 15, 2014||Option Execute||25,000||4.11|
|Jul 18, 2014||Automatic Sell||25,000||12.16|
|Jul 18, 2014||Option Execute||25,000||4.11|
|Jun 16, 2014||Automatic Sell||25,000||16.41|
|May 15, 2014||Automatic Sell||25,000||13.14|
|Apr 15, 2014||Automatic Sell||25,000||14.20|
|Mar 17, 2014||Automatic Sell||50,000||23.22|
|Mar 17, 2014||Option Execute||50,000||5.19|
|Mar 10, 2014||Disposition (Non Open Market)||4,000||n/a|
|Feb 18, 2014||Automatic Sell||50,000||18.09|
|Feb 18, 2014||Option Execute||50,000||5.19|
|Jan 15, 2014||Automatic Sell||50,000||18.51|
|Jan 15, 2014||Option Execute||50,000||6.39|
|Dec 18, 2013||Automatic Sell||50,000||12.47|
|Dec 18, 2013||Option Execute||50,000||6.39|
|Dec 12, 2013||Acquisition (Non Open Market)||75,000||n/a|
|Dec 12, 2013||Disposition (Non Open Market)||57,398||12.12|
|Nov 15, 2013||Automatic Sell||25,000||10.11|
|Oct 15, 2013||Automatic Sell||25,000||11.32|
|Oct 3, 2013||Disposition (Non Open Market)||13,500||n/a|
|Sep 16, 2013||Automatic Sell||25,000||11.29|
|Aug 15, 2013||Automatic Sell||25,000||10.12|
|Jul 17, 2013||Automatic Sell||25,000||10.00|
|Apr 16, 2013||Automatic Sell||190||10.00|
|Apr 15, 2013||Automatic Sell||5,000||10.00|
|Mar 28, 2013||Disposition (Non Open Market)||12,000||n/a|
|Feb 28, 2013||Automatic Sell||25,000||10.00|
|Jan 24, 2013||Automatic Sell||300||10.00|
|Jan 23, 2013||Automatic Sell||8,300||10.00|
|Dec 6, 2012||Acquisition (Non Open Market)||180,000||n/a|
|Jun 13, 2012||Disposition (Non Open Market)||11,000||n/a|
|Dec 8, 2011||Acquisition (Non Open Market)||150,000||n/a|
|Jun 1, 2011||Disposition (Non Open Market)||15,000||n/a|
John W. Larson has served as a member of our Board of Directors since January 1996. From February 2003 to December 2009, Mr. Larson served as a partner at the law firm of Morgan, Lewis & Bockius LLP. Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck) from 1969 until retiring in January 2003, except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the board of the Needham Funds, WageWorks Inc.and MBA Polymers, Inc. and on the boards of several privately held companies. Mr. Larson holds an L.L.B. and a B.A., with distinction, in economics, from Stanford University.
Steven J. Mento, Ph.D. has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento currently serves on the Boards of BIOCOM, the Biotechnology Organization (BIO), the BIO Health Section Governing Body, the BIO ECS Governing Body, the Donald P. Shiley BioSciences Center at SDSU Scientific Advisory Board, and Cal State San Marcos Advisory Council. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Saira Ramasastry has served as a member of our Board of Directors since June 2012. Since April 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice and business development solutions for life science companies. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, the Board of Directors of the American Liver Foundation and was formerly a special advisor to the California Institute for Regenerative Medicine (CIRM). Ms. Ramasastry currently serves on the boards of directors of Pain Therapeutics, Inc. and Repros Therapeutics Inc. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an M. Phil. in Management Studies from the University of Cambridge.
H. Stewart Parker has been a member of our Board of Directors since June 2014. Ms. Parker has over 30 years of experience in the biotechnology industry . She served as the chief executive officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from March 2011 to December 2013. In 1992, Ms. Parker founded Targeted Genetics Corporation, a publicly traded Seattle -based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in AAV gene therapy. She held the position of President and CEO and was a member of its board of directors from the company's inception until November 2008. Prior to founding Targeted Genetics, Ms. Parker served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. From February 1991 to January 1993, Ms. Parker served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves as a member of the board of directors for several for-profit and non-profit companies including C3 Jian Inc, Oncogenex Technologies Inc and IDRI and on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Stock transaction information provided by EDGAR Online. Sangamo BioSciences, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.